[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371671-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371671-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognosis-treatment-decision-making-and-value-a-qualitative-exploration-of-the-emerging-role-of-breast-cancer-prognostic-assays","Prognosis, treatment decision-making and value: A qualitative exploration of the emerging role of breast cancer prognostic assays","","Breast cancer prognostic assays are increasingly used to inform treatment decision-making, yet their integration into clinical practice and their impact on prognosis require careful examination for clinicians and patients. This qualitative study interviewed 15 international researcher-physician/scientist key opinion leaders experienced with five assays. Thematic analysis identified emerging roles of these tools in identifying overtreatment and unnecessary care, particularly to determine patients unlikely to benefit from adjuvant chemotherapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognosis-treatment-decision-making-and-value-a-qualitative-exploration-of-the-emerging-role-of-breast-cancer-prognostic-assays/371671/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognosis-treatment-decision-making-and-value-a-qualitative-exploration-of-the-emerging-role-of-breast-cancer-prognostic-assays/371671.png","ImageObject",300,407,{"name":42,"@type":43},"Terk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the objective of the study on breast cancer prognostic assays?","Question",{"text":63,"@type":64},"To explore perspectives on the use and integration of breast cancer prognostic assays in clinical care.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were participants and data collected and analyzed?",{"text":68,"@type":64},"Fifteen international researcher-physician/scientist key opinion leaders were interviewed virtually, recordings were transcribed verbatim, and data were analyzed using thematic analysis.",{"name":70,"@type":61,"acceptedAnswer":71},"What primary value did participants attribute to prognostic assays?",{"text":72,"@type":64},"They viewed the main value as identifying patients who will not benefit from adjuvant chemotherapy, helping reduce overtreatment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371671,1790240671,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","OPEN ACCESS  \nCitation: Parker G, Hogarth S, Fishman J, Miller FA (2025) Prognosis, treatment decisionmaking and value: A qualitative exploration of the emerging role of breast cancer prognostic assays. PLoS One 20(7): e0322509. [https://doi](https://doi). org/10.1371/journal.pone.0322509  \nEditor: Dongling Wu, Beth Israel Deaconess Medical Center, UNITED STATES OF AMERICA Received: July 7, 2024  \nAccepted: June 17, 2025  \nPublished: July 18, 2025  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0322509  \nCopyright: © 2025 Parker et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,  \nRESEARCH ARTICLE  \nPrognosis, treatment decision-making and value: A qualitative exploration of the emerging role of breast cancer prognostic assays  \nGillian Parker1☯, Stuart Hogarth2‡, Jennifer Fishman3‡, Fiona A. Miller1☯*  \n1 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada,  \n2 Department of Sociology, University of Cambridge, Cambridge, United Kingdom, 3 Department of Equity, Ethics, and Policy, McGill University, Montreal, QC, Canada  \n☯ These authors contributed equally to this work.  \n‡ SH and JF also contributed equally to this work.  \n* [fiona.miller@utoronto.ca](fiona.miller@utoronto.ca)  \nAbstract  \nBackground  \nBreast cancer prognostic assays are emerging as tools used by physicians in the cancer treatment decision-making process. This technology is new, and we must interrogate the integration of these assays into clinical practice and their effect on prognosis and treatment for both providers and patients. The objective of this study was to explore perspectives on the use and integration of breast cancer prognostic assays in clinical care.  \nMethods  \n15 international researcher-physician/scientist key opinion leaders who had conducted studies on breast cancer prognostic assays were interviewed. Participants had conducted studies using five different assays. The interview guide was developed through a literature review and leveraged extensive data collected on key clinical utility outcomes for the assays. All interviews were conducted virtually, recorded, and transcribed verbatim. Data were analysed using thematic analysis.  \nResults  \nThree novel themes emerged from participant’s perspectives on the use and value of these assays. The emerging role of prognostic assays to identify overtreatment and unnecessary care was highlighted by the majority of participants. The primary value of these tools is to identify patients who will not benefit from adjuvant chemotherapy. Participants reported that current standard practice is to overtreat and portrayed the binary or definitive results of these assays as an important tool to reduce overtreatment. Participants also provided insights into deliberate efforts to integrate the assays  \nPLOS One | [https://doi.org/10.1371/journal.pone.0322509](https://doi.org/10.1371/journal.pone.0322509) July 18, 2025 1 / 11  \nand reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data are within the paper and its Supporting  Information files.  \nFunding: Funded by an investigator-initiated grant to FAM from the Canadian Institutes of Health Research (PJT 148805) . The fundershad no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.  \nCompeting interests: Competing interests:  \nNone declared.  \ninto clinical practice and how improved quality of life and reduction in overtreatment was positioned to justify high cost of the assay","cbCaisMZOOqxKeX4","https://ap.wps.com/l/cbCaisMZOOqxKeX4","pdf",378519,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Clinical utility and evaluation debates","[{\"question\":\"What was the objective of the study on breast cancer prognostic assays?\",\"answer\":\"To explore perspectives on the use and integration of breast cancer prognostic assays in clinical care.\"},{\"question\":\"How were participants and data collected and analyzed?\",\"answer\":\"Fifteen international researcher-physician/scientist key opinion leaders were interviewed virtually, recordings were transcribed verbatim, and data were analyzed using thematic analysis.\"},{\"question\":\"What primary value did participants attribute to prognostic assays?\",\"answer\":\"They viewed the main value as identifying patients who will not benefit from adjuvant chemotherapy, helping reduce overtreatment.\"}]","Prognosis, treatment decision-making and value: A qualitative exploration of the emerging role of breast cancer prognostic assays | PDF",1790192578,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ce67ebc4bdf1a44422edda6dd609843.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a02f020828a635bc9490cf53e8081930.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbca05c477d40ba2cb0b63a34017253f.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0267e0a646600382dda329d126687eb0.webp",980,1268]